PHI-101

PHI-101

• CAS Number: 2127107-15-5
• UNSPSC Description: PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 has potential for research in relapsed or refractory acute myeloid leukemia (AML)[1].
• Target Antigen: FLT3
• Type: Reference compound
• Related Pathways: Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/phi-101.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: NC(NC1=C(SC(C#CC2=CC(F)=CC=C2)=C1)C(N[C@H]3CCCNC3)=O)=O
• Molecular Weight: 386.44
• References & Citations: [1]Nam K Y, et al. PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia[J]. Blood, 2020, 136: 28.
• Shipping Conditions: Room Temperature
• Clinical Information: Phase 1